SOLICITATION NOTICE
66 -- Purchase of ACUSON S2000 Ultrasound Imaging System
- Notice Date
- 1/18/2011
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- NOI-1922830
- Archive Date
- 2/11/2011
- Point of Contact
- Liem T Nguyen, Phone: 3014358780
- E-Mail Address
-
ln18x@nih.gov
(ln18x@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Institute on Drug Abuse (NIDA), Office of Acquisitions Station Support Simplified Acquisitions Branch on behalf of the National Institute of Neurological Disorders and Stroke (NINDS) intends to negotiate, on a non-competitive basis, with SIEMENS MEDICAL SOLUTIONS USA INC., 51 Valley Stream Parkway, Malvern, PA 19355, for an ACUSON S2000 Ultrasound System. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority of FAR 13.106-1(b)(1) and FAR 13.501 (a)(1) to use Simplified Acquisition Procedure for commercial items. The North American Industry Classification System Code for this acquisition is 334516 and the size standard is 500 employees. The NINDS Division of Intramural Research is conducting studies on Muscular Dystrophy in children using Acoustic Radiation Force Impulse Imaging. Muscular dystrophies are a genetically heterogeneous group of degenerative muscle disorders, most commonly with onset in childhood. The NINDS researchers hypothesize that acoustic radiation force (ARF) imaging can be used to non-invasively assess the stiffness of dystrophic muscle tissue and that the degree of stiffness of the tissue is dependent on the degree and extent of fibrosis, inflammation, and fatty deposition within the muscle. The NINDS researchers further hypothesize that the degree of physical tissue change as measured by MP-ARF will directly reflect the severity of involvement of the muscle and thereby correlated with the overall clinical state of the patient, thus qualifying ARF imaging as a noninvasive biomarker for the disease. The NINDS researchers plan to validate MP-ARF imaging in eighteen (18) children and young adults (ages 6-21) with Duchenne muscular dystrophy and with congenital muscular dystrophy (collagen VI related and merosin deficient types) over time and compared to a cohort of normal children and young adults. ARF ultrasound has the capability follow the development of fibro-fatty changes in the muscle by noninvasive means and thus could be an important tool to define the natural history of the muscular dystrophies and to serve as an outcome measure for therapeutic trials in the muscular dystrophies, including those that directly indirectly modulate fibrosis. For this to become a clinically useful tool to be applicable to predominantly pediatric patient population, it should ideally be noninvasive, not require sedation, and have the potential for a safe serial application. Ultrasound imaging ideally fulfills these requirements. NINDS staff has investigated the market and found that SIEMENS S-2000 is the only high-end ultrasound machine capable of high resolution imaging up to 18MHz, optimized for musculoskeletal applications. The SIEMENS S-2000 is equipped with elastography and with ARFI (acoustic radiation force impulse) imaging capability, referred as "Virtual-Touch" imaging. The SIEMENS S-2000 currently is the only machine approved for human use that has ARFI capability. It is essential that the SIEMENS S-2000 with ARFI capability be purchased to allow the NINDS researchers to continue with the ongoing studies. This SIEMENS S-2000 is available only through SIEMENS. No other source of supplies or products will satisfy the agency's requirement. Delivery will be F.O.B. Destination and to be shipped to NIH Bethesda campus. Ultrasound Apps Training 2 days is to be included and provided by the vendor. No solicitation package will be issued. This notice of intent is not a request for competitive quotations; however, the Government will consider responses submitted to ln18x@nih.gov on or before 2:00 PM ET January 27, 2011. All information furnished must be in writing and must contain sufficient detail to allow the government to determine if it can meet the above specifications described herein. A determination by the Government not to compete the proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Please reference the announcement number NOI-1922830 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/NOI-1922830/listing.html)
- Record
- SN02361629-W 20110120/110118233908-566c18cf20a2a9a2d180c2c4792c0e0b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |